PL191027B1 - Pochodna α,α-dipodstawionej aryloalkiloaminy, kompozycja farmaceutyczna i zastosowanie α,α-dipodstawionej aryloalkiloaminy - Google Patents

Pochodna α,α-dipodstawionej aryloalkiloaminy, kompozycja farmaceutyczna i zastosowanie α,α-dipodstawionej aryloalkiloaminy

Info

Publication number
PL191027B1
PL191027B1 PL329314A PL32931497A PL191027B1 PL 191027 B1 PL191027 B1 PL 191027B1 PL 329314 A PL329314 A PL 329314A PL 32931497 A PL32931497 A PL 32931497A PL 191027 B1 PL191027 B1 PL 191027B1
Authority
PL
Poland
Prior art keywords
phenyl
group
compound
dimethyl
methoxyphenyl
Prior art date
Application number
PL329314A
Other languages
English (en)
Polish (pl)
Other versions
PL329314A1 (en
Inventor
Wagenen Bradford C. Van
Mar Eric G. Del
Derek Sheehan
Robert M. Barmore
Richard M. Keenan
Nikesh R. Kotecha
Mervyn Thompson
James F. Callahan
Original Assignee
Nps Pharma Inc
Smithkline Beecham
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nps Pharma Inc, Smithkline Beecham, Smithkline Beecham Plc filed Critical Nps Pharma Inc
Publication of PL329314A1 publication Critical patent/PL329314A1/xx
Publication of PL191027B1 publication Critical patent/PL191027B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
PL329314A 1996-04-09 1997-04-04 Pochodna α,α-dipodstawionej aryloalkiloaminy, kompozycja farmaceutyczna i zastosowanie α,α-dipodstawionej aryloalkiloaminy PL191027B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62960896A 1996-04-09 1996-04-09
US3226396P 1996-12-03 1996-12-03
PCT/US1997/005558 WO1997037967A1 (en) 1996-04-09 1997-04-04 Calcilytic compounds

Publications (2)

Publication Number Publication Date
PL329314A1 PL329314A1 (en) 1999-03-15
PL191027B1 true PL191027B1 (pl) 2006-03-31

Family

ID=26708193

Family Applications (1)

Application Number Title Priority Date Filing Date
PL329314A PL191027B1 (pl) 1996-04-09 1997-04-04 Pochodna α,α-dipodstawionej aryloalkiloaminy, kompozycja farmaceutyczna i zastosowanie α,α-dipodstawionej aryloalkiloaminy

Country Status (18)

Country Link
US (2) US6022894A (enExample)
EP (1) EP0901459B1 (enExample)
JP (1) JP2001501584A (enExample)
CN (1) CN1254465C (enExample)
AR (1) AR008586A1 (enExample)
AT (1) ATE298739T1 (enExample)
AU (1) AU726659B2 (enExample)
BR (1) BR9708632A (enExample)
CA (1) CA2251331C (enExample)
CO (1) CO4820431A1 (enExample)
DE (1) DE69733649T2 (enExample)
EA (1) EA002984B1 (enExample)
IL (1) IL126458A (enExample)
NZ (1) NZ332068A (enExample)
PL (1) PL191027B1 (enExample)
SA (1) SA97180135B1 (enExample)
SG (1) SG99290A1 (enExample)
WO (1) WO1997037967A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US7202261B2 (en) * 1996-12-03 2007-04-10 Nps Pharmaceuticals, Inc. Calcilytic compounds
UY24949A1 (es) * 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
AU2351699A (en) 1998-01-30 1999-08-16 Brigham And Women's Hospital The human calcium-sensing receptor in the detection and treatment of cancer
US7262280B1 (en) 1998-04-03 2007-08-28 Nps Pharmaceuticals, Inc. G-protein fusion receptors and constructs encoding same
AR018177A1 (es) 1998-04-08 2001-10-31 Smithkline Beecham Corp Compuestos calciliticos, una composicion farmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento.
CA2245903A1 (en) * 1998-09-28 2000-03-28 Mcgill University Use of pex in the treatment of metabolic bone diseases
PE20001456A1 (es) * 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
CO5180628A1 (es) * 1999-07-31 2002-07-30 Smithkline Beecham Corp Compuestos calcioliticos
AR030684A1 (es) * 2000-01-24 2003-09-03 Smithkline Beecham Corp Compuestos calciliticos, uso de dichos compuestos en la manufactura de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
US20030018203A1 (en) * 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
DE60131781T2 (de) * 2000-07-21 2008-12-24 Smithkline Beecham Corp. Kalzilytische verbindungen
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US6916956B2 (en) 2000-08-11 2005-07-12 Japan Tobacco, Inc. Calcium receptor antagonist
JP2004514659A (ja) * 2000-10-25 2004-05-20 スミスクライン・ビーチャム・コーポレイション カルシライティック化合物
MXPA04009959A (es) 2002-04-12 2004-12-13 Schering Corp Ligandos del receptor acoplado a la proteina g y metodos.
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
FR2847250B1 (fr) * 2002-11-15 2006-09-22 Oreal Composition, notamment cosmetique, comprenant une amine secondaire ou tertiaire
TWI316511B (en) 2002-11-26 2009-11-01 Smithkline Beecham Corp Calcilytic compounds
WO2004069793A2 (en) * 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Novel 2-substituted cyclic amines as calcium sensing receptor modulators
US7205322B2 (en) * 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
CA2513738C (en) 2003-04-23 2010-04-06 Japan Tobacco Inc. Casr antagonist
US7265145B2 (en) * 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
CA2527203C (en) 2003-05-28 2010-08-17 Japan Tobacco Inc. Casr antagonist
WO2005065050A2 (ja) 2003-12-25 2005-07-21 Asahi Kasei Pharma Corporation ２環化合物
WO2005077892A1 (en) * 2004-02-06 2005-08-25 Smithkline Beecham Corporation Calcilytic compounds
US7648965B2 (en) * 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US7531518B2 (en) 2004-05-14 2009-05-12 Unigene Laboratories Inc. Method for fostering bone formation and preservation
PL1757582T3 (pl) 2004-05-28 2016-04-29 Mitsubishi Tanabe Pharma Corp Aryloalkiloaminy i sposób ich wytwarzania
US20080069814A1 (en) * 2005-01-05 2008-03-20 Novacea, Inc. Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof
BRPI0610077A2 (pt) * 2005-04-22 2010-05-25 Novacea Inc tratamento, prevenção e atenuação de distúrbios pulmonares associados à quimioterapia ou radioterapia com compostos de vitamina d ativos ou miméticos destes
FR2885129B1 (fr) 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
US20060293667A1 (en) * 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
ES2400693T3 (es) 2005-09-02 2013-04-11 Amgen Inc. Regulación del equilibrio de fluido intestinal usando calcimiméticos
DE602006010905D1 (de) 2005-11-25 2010-01-14 Galapagos Sas Harnstoff-derivate als calcium-rezeptor-modulatoren
WO2009055631A1 (en) * 2007-10-25 2009-04-30 Smithkline Beecham Corporation Calcilytic compounds
KR101479371B1 (ko) * 2008-06-05 2015-01-05 아사히 가세이 파마 가부시키가이샤 술폰아미드 화합물 및 그 용도
EP2196461A1 (de) 2008-12-15 2010-06-16 Bayer CropScience AG 4-Amino-1,2,3-benzoxathiazin-Derivate als Pestizide
WO2010103429A1 (en) 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
CN103601645B (zh) * 2013-11-07 2016-05-25 上海适济生物科技有限公司 1-(苯乙基氨基)丙烷-2-醇类化合物或其盐的制备方法
WO2019153216A1 (zh) * 2018-02-09 2019-08-15 北京梅尔森医药技术开发有限公司 取代芳基胺醇化合物及其制备方法和用途
WO2021110859A1 (en) * 2019-12-05 2021-06-10 Syngenta Crop Protection Ag One step process for the preparation of phenyl ethyl amine derivatives
CN116199605A (zh) * 2023-02-27 2023-06-02 上海睿腾医药科技有限公司 一种5-氯-2-羟基-二甲基苯磺酰胺的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE298506C (enExample) *
GB1129072A (en) * 1966-02-01 1968-10-02 Ici Ltd Benzofuran and indole derivatives
GB1058822A (en) * 1963-07-30 1967-02-15 Ici Ltd 3-amino-2-hydroxypropoxy heterocyclic derivatives
GB1199037A (en) * 1967-09-27 1970-07-15 Ici Ltd Alkanolamine Derivatives
ES410417A1 (es) * 1973-01-08 1976-01-01 Andreu Sa Dr Procedimiento para la obtencion de aminoalcoholes derivadosdel p-acetamidofenol.
SE388849B (sv) * 1974-02-14 1976-10-18 Haessle Ab Forfarande for framstellning av nya aminer med beta-receptorstimulerande verkan
DE2530613A1 (de) * 1974-11-01 1976-05-06 Haessle Ab Aminderivate, verfahren zu deren herstellung und sie enthaltende arzneimittel
US4067904A (en) * 1975-12-19 1978-01-10 Mead Johnson & Company Alkylsulfonylphenoxypropanolamine derivatives
JPS5936617B2 (ja) * 1976-03-05 1984-09-05 大塚製薬株式会社 カルボスチリル誘導体
CH619453A5 (enExample) * 1976-03-17 1980-09-30 Otsuka Pharma Co Ltd
DE2830211A1 (de) * 1977-07-21 1979-02-01 Sandoz Ag Substituierte indol-derivate, ihre herstellung und verwendung
US4235919A (en) * 1977-07-21 1980-11-25 Sandoz Ltd. 1-(Indol-4-yloxy)-3-(2-substituted amino)-2-propanols and pharmaceutical use thereof
EP0002792A1 (en) * 1978-01-03 1979-07-11 Sandoz Ag 3-Aminopropoxyaryl derivatives, their preparation and pharmaceutical compositions containing them
DK267779A (da) * 1978-06-27 1979-12-28 Merck & Co Inc Fr&mgangsmaade til fremstilling af n-aralkylamino-propoxycyanopyridiner
CH636856A5 (en) * 1978-07-17 1983-06-30 Sandoz Ag 4-(3-Aminopropoxy)indole derivatives, their preparation and medicines containing them
DE2914166A1 (de) * 1979-04-07 1980-10-23 Beiersdorf Ag Arylsubstituierte furane und verfahren zu ihrer herstellung
ES480066A1 (es) * 1979-04-28 1980-04-01 Especialid Latin Medicam Unive Procedimiento de obtencion de 1-4-cloro-&,&-dimetil-benceno-etanamino-2-oxi-3 ariloxi propanos.
DE2943406A1 (de) * 1979-10-26 1981-05-07 Basf Ag, 6700 Ludwigshafen Aminoderivate des 2-methyl-5-(2-hydroxystyryl)-1,3,4-thiadiazols
DE2944222A1 (de) * 1979-11-02 1981-05-14 Basf Ag, 6700 Ludwigshafen Neue aminoderivate des 1,2-benzisothiazols
JPS568319A (en) * 1980-03-26 1981-01-28 Otsuka Pharmaceut Co Ltd Antihistamine
US4332787A (en) * 1980-06-23 1982-06-01 The Massachusetts General Hospital Assay for beta-adrenergic antagonists and antibody therefor
JPS5780321A (en) * 1980-11-05 1982-05-19 Otsuka Pharmaceut Co Ltd Cardiotonic agent
US4376125A (en) * 1980-11-05 1983-03-08 University Of Virginia Alumni Patents Foundation Aminobenzlpropranolol and pharmaceutical preparation thereof
EP0095454A3 (de) * 1982-05-13 1985-04-03 Gerot-Pharmazeutika Gesellschaft m.b.H. Neue kernsubstituierte Pyrogallol-Derivate
DE3301198A1 (de) * 1983-01-15 1984-07-19 Hoechst Ag, 6230 Frankfurt N-arylalkylamin-3-propoxypyridin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung
US4517188A (en) * 1983-05-09 1985-05-14 Mead Johnson & Company 1-Pyrimidinyloxy-3-hetaryl-alkylamino-2-propanols
IL77594A (en) * 1985-01-15 1989-12-15 Glaxo Group Ltd 2-substituted-3,4-dihydroxyphenethylamine derivatives,their preparation and pharmaceutical compositions containing them
GB2192394A (en) * 1986-07-11 1988-01-13 Glaxo Group Ltd Amine derivatives
DK391189A (da) * 1988-08-10 1990-02-11 Otsuka Pharma Co Ltd Carbostyrilderivater
DE4040186A1 (de) * 1989-12-20 1991-06-27 Hoechst Ag Hypoglykaemisch aktive propandiolaminderivate mit insulin-aehnlicher wirkung und deren verwendung, neue propandiolaminderivate, diese substanzen enthaltende pharmazeutische zubereitungen und ihre verwendung zur behandlung von krankheiten
DE4017019A1 (de) * 1990-05-26 1991-11-28 Hoechst Ag Verwendung von substituierten ss-hydroxyethylaminen als potente hemmstoffe der exoenzyme von pilzen
DK0584222T3 (da) * 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
DE69233572T2 (de) * 1991-08-23 2006-08-31 NPS Pharmaceuticals, Inc., Salt Lake City Screening-Verfahren für Kalzium-Rezeptor aktive Verbindungen
AU702629B2 (en) * 1991-08-23 1999-02-25 Nps Pharmaceuticals, Inc. Calcium receptor-active arylalkyl amines
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
WO1994018959A1 (en) * 1993-02-23 1994-09-01 Brigham And Women's Hospital, Inc. Calcium receptor-active molecules
GB9312893D0 (en) * 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.

Also Published As

Publication number Publication date
CA2251331A1 (en) 1997-10-16
EP0901459B1 (en) 2005-06-29
NZ332068A (en) 2001-03-30
EA199800913A1 (ru) 1999-06-24
IL126458A (en) 2004-06-20
SG99290A1 (en) 2003-10-27
ATE298739T1 (de) 2005-07-15
JP2001501584A (ja) 2001-02-06
SA97180135B1 (ar) 2006-06-12
HK1018899A1 (en) 2000-01-07
CN1254465C (zh) 2006-05-03
DE69733649T2 (de) 2006-05-18
PL329314A1 (en) 1999-03-15
CA2251331C (en) 2009-06-09
CN1221401A (zh) 1999-06-30
BR9708632A (pt) 2000-01-18
EA002984B1 (ru) 2002-12-26
AR008586A1 (es) 2000-02-09
AU726659B2 (en) 2000-11-16
DE69733649D1 (de) 2005-08-04
AU2607097A (en) 1997-10-29
US6521667B1 (en) 2003-02-18
IL126458A0 (en) 1999-08-17
WO1997037967A1 (en) 1997-10-16
US6022894A (en) 2000-02-08
EP0901459A1 (en) 1999-03-17
CO4820431A1 (es) 1999-07-28

Similar Documents

Publication Publication Date Title
PL191027B1 (pl) Pochodna α,α-dipodstawionej aryloalkiloaminy, kompozycja farmaceutyczna i zastosowanie α,α-dipodstawionej aryloalkiloaminy
JP4431609B2 (ja) 無機イオン活性化合物
US6001884A (en) Calcium receptor-active molecules
JP2882882B2 (ja) カルシウム受容体活性化合物
EP1466888A1 (en) Calcium receptor-active arylalkyl amines
US6432656B1 (en) Calcilytic compounds
US6335338B1 (en) Calcilytic compounds
EP0998283A1 (en) Calcilytic compounds
US7202261B2 (en) Calcilytic compounds
US6291459B1 (en) Calcilytic compounds
US6818660B2 (en) Calcilytic compounds
US20080234370A1 (en) Calcilytic Compounds
US20070249702A1 (en) Calcilytic compounds
HK1018899B (en) Calcilytic compounds
HK1102806B (en) Inorganic ion receptor-active compounds
HK1070351A (en) Calcium receptor-active arylalkyl amines
HK1012620B (en) Calcium receptor-active arylalkyl amines
HK1077807A (en) Calcium receptor-active compounds